US Bancorp’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.63K Buy
265
+21
+9% +$689 ﹤0.01% 3407
2025
Q4
$7.75K Hold
244
﹤0.01% 3410
2025
Q3
$5.73K Sell
244
-15
-6% -$257 ﹤0.01% 3497
2025
Q2
$2.94K Sell
259
-10,963
-98% -$104K ﹤0.01% 3783
2025
Q1
$74.6K Buy
11,222
+11,108
+9,744% +$104K ﹤0.01% 2538
2024
Q4
$1.26K Sell
114
-70
-38% -$860 ﹤0.01% 3930
2024
Q3
$2.26K Sell
184
-212
-54% -$3K ﹤0.01% 3762
2024
Q2
$5.35K Buy
+396
New +$5.35K ﹤0.01% 3488
2023
Q4
Sell
-538
Closed -$2.12K 4146
2023
Q3
$2.12K Sell
538
-283
-34% -$1.86K ﹤0.01% 3644
2023
Q2
$8.73K Sell
821
-80
-9% -$851 ﹤0.01% 3311
2023
Q1
$7.5K Buy
901
+410
+84% +$3.7K ﹤0.01% 3387
2022
Q4
$4.53K Sell
491
-944
-66% -$9.82K ﹤0.01% 3540
2022
Q3
$18K Sell
1,435
-79
-5% -$1.26K ﹤0.01% 3081
2022
Q2
$20K Buy
1,514
+1,151
+317% +$17.5K ﹤0.01% 3052
2022
Q1
$8K Buy
363
+242
+200% +$4.85K ﹤0.01% 3471
2021
Q4
$3K Buy
+121
New +$2.89K ﹤0.01% 3829
2020
Q4
Sell
-600
Closed -$20K 3878
2020
Q3
$20K Hold
600
﹤0.01% 2818
2020
Q2
$14K Hold
600
﹤0.01% 2983
2020
Q1
$14K Buy
+600
New +$14.8K ﹤0.01% 2909

Other funds holding STOK

US Bancorp's STOK Position: Q1 2026 in Review

US Bancorp increased its Stoke Therapeutics (STOK) stake by 8.6% in Q1 2026, buying an estimated $689 and bringing the position to 265 shares worth $8.63K. The position accounts for ﹤0.01% of the portfolio, ranked #3407.

US Bancorp first reported a position in STOK in Q1 2020 and has held it in 19 quarters since. The position peaked at $74.6K in Q1 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • US Bancorp held 265 shares of Stoke Therapeutics worth $8.63K as of Q1 2026.
  • US Bancorp bought 21 Stoke Therapeutics shares in Q1 2026, an estimated $689.
  • Stoke Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3407 holding.
  • US Bancorp first reported a position in Stoke Therapeutics in Q1 2020 and has held it in 19 quarters since.
  • US Bancorp's Stoke Therapeutics position peaked at $74.6K in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.